Clinical Trials Browser

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

NCT02360111 2019-07-24

GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

Phase NA Terminated

3 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Renal Insufficiency

NCT00721734 2017-05-02

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Phase 2 Completed

50 enrolled 33 charts

Plasma cell

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01853046 2017-02-20

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Phase 1 Completed

24 enrolled 30 charts

Neoplasms, Renal Insufficiency

NCT01569815 2015-10-19

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Phase 1 Completed

32 enrolled 16 charts

Lymphoid

Lymphoma, Follicular, Renal Insufficiency

Clinical Trials

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

BRIDGE

LVPK

OPTIMAL

Study of Copanlisib in Hepatic or Renal Impairment

RENAL

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function